86 related articles for article (PubMed ID: 3456073)
1. Cell-cycle prognostic value in adult acute myeloid leukemia. The choice of the best variables.
Ffrench M; Bryon PA; Fiere D; Vu Van H; Guyotat D; Extra JM; Viala JJ
Leuk Res; 1986; 10(1):51-7. PubMed ID: 3456073
[TBL] [Abstract][Full Text] [Related]
2. Adult acute lymphoblastic leukaemia: is cell proliferation related to other clinical and biological features?
Ffrench M; Manel AM; Magaud JP; Fiere D; Adeleine P; Guyotat D; Bryon PA
Br J Haematol; 1987 Apr; 65(4):419-23. PubMed ID: 3472588
[TBL] [Abstract][Full Text] [Related]
3. [Simultaneous determination of cellular DNA and proteins by cytofluorimetry. Application to acute leukemia in adults].
Ffrench M; Fiere D; Bryon PA; Cordier G; Viala JJ
Pathol Biol (Paris); 1984 Feb; 32(2):139-43. PubMed ID: 6366709
[TBL] [Abstract][Full Text] [Related]
4. Cell-cycle, protein content, and nuclear size in acute myeloid leukemia.
Ffrench M; Bryon PA; Fiere D; Vu Van H; Gentilhomme O; Adeleine P; Viala JJ
Cytometry; 1985 Jan; 6(1):47-53. PubMed ID: 3855395
[TBL] [Abstract][Full Text] [Related]
5. Cell kinetics in acute lymphoblastic leukaemia: comparative analysis between adults and children.
Ffrench M; Magaud JP; Manel AM; Adeleine P; Devaux Y; Fiere D; Philippe N; Souillet G; Bryon PA
Br J Cancer; 1989 Mar; 59(3):401-6. PubMed ID: 2930706
[TBL] [Abstract][Full Text] [Related]
6. DNA, RNA, and protein content in adult acute myeloid leukemia: effects of cytostatic drugs in vivo.
Wolowiec D; Ffrench M; Tigaud JD; Treille-Ritouet D; Archimbaud E; Bryon PA
Leukemia; 1988 Aug; 2(8):534-9. PubMed ID: 3166079
[TBL] [Abstract][Full Text] [Related]
7. Prognotic significance of pretreatment proliferative activity in adult acute leukemia.
Hart JS; George SL; Frei E; Bodey GP; Nickerson RC; Freireich EJ
Cancer; 1977 Apr; 39(4):1603-17. PubMed ID: 265746
[TBL] [Abstract][Full Text] [Related]
8. Flow cytometric analysis of deoxyribonucleic acid (DNA) content in adult leukemia.
Hirosawa S; Maruyama Y; Murakami N; Kudo H
Jpn J Med; 1984 Aug; 23(3):220-7. PubMed ID: 6593480
[TBL] [Abstract][Full Text] [Related]
9. Characteristics and prognostic factors of acute myeloid leukemia with t (8; 21) (q22; q22).
Lai YY; Qiu JY; Jiang B; Lu XJ; Huang XJ; Zhang Y; Liu YR; Shi HL; Lu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct; 13(5):733-40. PubMed ID: 16277833
[TBL] [Abstract][Full Text] [Related]
10. Cell kinetics with in vivo bromodeoxyuridine assay, proliferating cell nuclear antigen expression, and flow cytometric analysis. Prognostic significance in acute nonlymphoblastic leukemia.
Giordano M; Danova M; Mazzini G; Gobbi P; Riccardi A
Cancer; 1993 May; 71(9):2739-45. PubMed ID: 8096794
[TBL] [Abstract][Full Text] [Related]
11. Low proportion of G0-phase cells during induction chemotherapy correlates with subsequent remission in acute myeloid leukemia.
Kamikubo KH; Ogata K; An E; Dan K
Int J Hematol; 2000 Apr; 71(3):249-55. PubMed ID: 10846830
[TBL] [Abstract][Full Text] [Related]
12. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry.
Hulegårdh E; Nilsson C; Lazarevic V; Garelius H; Antunovic P; Rangert Derolf Å; Möllgård L; Uggla B; Wennström L; Wahlin A; Höglund M; Juliusson G; Stockelberg D; Lehmann S
Am J Hematol; 2015 Mar; 90(3):208-14. PubMed ID: 25421221
[TBL] [Abstract][Full Text] [Related]
13. Correlation of the proliferative index of residual leukemia with outcome in patients treated with sequential high dose ara-C and asparaginase.
Powell BL; Kute TE; Craig JB; Lyerly ES; Gregory BW; Do KA; Contento MM; Capizzi RL
Leukemia; 1990 May; 4(5):316-20. PubMed ID: 2388477
[TBL] [Abstract][Full Text] [Related]
14. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
Terwijn M; van Putten WL; Kelder A; van der Velden VH; Brooimans RA; Pabst T; Maertens J; Boeckx N; de Greef GE; Valk PJ; Preijers FW; Huijgens PC; Dräger AM; Schanz U; Jongen-Lavrecic M; Biemond BJ; Passweg JR; van Gelder M; Wijermans P; Graux C; Bargetzi M; Legdeur MC; Kuball J; de Weerdt O; Chalandon Y; Hess U; Verdonck LF; Gratama JW; Oussoren YJ; Scholten WJ; Slomp J; Snel AN; Vekemans MC; Löwenberg B; Ossenkoppele GJ; Schuurhuis GJ
J Clin Oncol; 2013 Nov; 31(31):3889-97. PubMed ID: 24062400
[TBL] [Abstract][Full Text] [Related]
15. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
Ravandi F; Jorgensen J; Borthakur G; Jabbour E; Kadia T; Pierce S; Brandt M; Wang S; Konoplev S; Wang X; Huang X; Daver N; DiNardo C; Andreeff M; Konopleva M; Estrov Z; Garcia-Manero G; Cortes J; Kantarjian H
Cancer; 2017 Feb; 123(3):426-435. PubMed ID: 27657543
[TBL] [Abstract][Full Text] [Related]
16. Quantitative cytology in leukemia research.
Barlogie B; Maddox AM; Johnston DA; Raber MN; Drewinko B; Keating MJ; Freireich EJ
Blood Cells; 1983; 9(1):35-55. PubMed ID: 6344934
[TBL] [Abstract][Full Text] [Related]
17. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
Pituch-Noworolska A
Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
[TBL] [Abstract][Full Text] [Related]
18. Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
Jongen-Lavrencic M; Grob T; Hanekamp D; Kavelaars FG; Al Hinai A; Zeilemaker A; Erpelinck-Verschueren CAJ; Gradowska PL; Meijer R; Cloos J; Biemond BJ; Graux C; van Marwijk Kooy M; Manz MG; Pabst T; Passweg JR; Havelange V; Ossenkoppele GJ; Sanders MA; Schuurhuis GJ; Löwenberg B; Valk PJM
N Engl J Med; 2018 Mar; 378(13):1189-1199. PubMed ID: 29601269
[TBL] [Abstract][Full Text] [Related]
19. Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study.
Bao Y; Zhao J; Li ZZ
Clin Transl Oncol; 2018 Jul; 20(7):870-880. PubMed ID: 29181696
[TBL] [Abstract][Full Text] [Related]
20. HAG regimen improves survival in adult patients with hypocellular acute myeloid leukemia.
Hu X; Fu W; Wang L; Gao L; Lü S; Xi H; Qiu H; Chen L; Chen J; Ni X; Xu X; Zhang W; Yang J; Wang J; Song X
Oncotarget; 2016 Jan; 7(3):3623-34. PubMed ID: 26497216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
